Agios entered a distribution agreement with NewBridge in 2024, focusing on regulatory filings and commercialisation.

Alpha Thalassemia is the most predominant genetic disorder affecting 15.30% of the population. Genetic disorders are not curable, but they can be prevented with IGENOMIX's Carrier Genetic Test (CGT).

With the positive data generated in the Phase 3 ENERGIZE-T and ENERGIZE studies of mitapivat in patients with alpha- or beta- thalassemia regardless of transfusion needs, the company intends to ...